FFM

Fairmount Funds Management Portfolio holdings

AUM $772M
1-Year Est. Return 35.05%
This Quarter Est. Return
1 Year Est. Return
+35.05%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$645M
AUM Growth
-$361M
Cap. Flow
Cap. Flow %
Top 10 Hldgs %
Holding
17
New
Increased
Reduced
Closed

Top Buys

No buys this quarter

Top Sells

1 +$76.3M
2 +$41.8M
3 +$39.3M
4
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$24.3M
5
ANAB icon
AnaptysBio
ANAB
+$24.1M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
AXSM icon
1
Axsome Therapeutics
AXSM
$6.38B
$95.1M 14.75%
815,176
-653,807
APGE icon
2
Apogee Therapeutics
APGE
$3.73B
$76.5M 11.87%
2,048,647
SYRE icon
3
Spyre Therapeutics
SYRE
$1.74B
$64.8M 10.06%
4,018,101
ELVN icon
4
Enliven Therapeutics
ELVN
$1.27B
$63M 9.78%
3,202,798
NUVL icon
5
Nuvalent
NUVL
$6.67B
$51.6M 8%
727,563
-590,101
DNTH icon
6
Dianthus Therapeutics
DNTH
$1.42B
$49M 7.6%
2,700,691
VRDN icon
7
Viridian Therapeutics
VRDN
$1.98B
$46.4M 7.21%
3,445,813
SRRK icon
8
Scholar Rock
SRRK
$2.69B
$44.2M 6.85%
1,374,031
-588,922
COGT icon
9
Cogent Biosciences
COGT
$2.29B
$37.3M 5.79%
6,225,641
ORKA
10
Oruka Therapeutics
ORKA
$1.33B
$34.6M 5.37%
3,371,922
KNSA icon
11
Kiniksa Pharmaceuticals
KNSA
$2.86B
$24.5M 3.8%
1,102,248
-1,092,093
ATXS icon
12
Astria Therapeutics
ATXS
$676M
$19M 2.94%
3,554,129
ZBIO
13
Zenas BioPharma
ZBIO
$1.13B
$15M 2.32%
1,892,806
IKT icon
14
Inhibikase Therapeutics
IKT
$117M
$13.4M 2.08%
6,125,000
BCAX
15
Bicara Therapeutics
BCAX
$997M
$10.2M 1.59%
784,170
-499,999
ANAB icon
16
AnaptysBio
ANAB
$969M
-1,816,466
DAWN icon
17
Day One Biopharmaceuticals
DAWN
$738M
-3,103,448